Published on: 27 Feb, 2026

Metabolic dysfunction-associated steatotic liver disease (MASLD) has rapidly become a leading cause of hepatocellular carcinoma (HCC) worldwide. Unlike traditional liver diseases where cirrhosis is the main precursor to HCC, a significant proportion of MASLD-related HCC cases arise in noncirrhotic livers. This divergence challenges existing surveillance paradigms and underscores the urgent need for refined risk assessment strategies tailored to MASLD’s unique pathophysiology.

The Emerging Challenge: Noncirrhotic MASLD and Hepatocellular Carcinoma Risk

Historically, cirrhosis has been the cornerstone for identifying patients at risk for HCC. However, MASLD defies this model by exhibiting a substantial number of HCC cases without prior cirrhosis. This phenomenon results from early pathogenic mechanisms like metabolic dysregulation, lipotoxicity, and chronic low-grade inflammation, which can independently initiate hepatocarcinogenesis. Despite the low annual incidence of HCC in noncirrhotic MASLD, the sheer global prevalence of MASLD translates into a significant absolute burden of cancer cases. Therefore, healthcare professionals must recognize that relying solely on fibrosis stage to define HCC risk is insufficient in MASLD populations.

Beyond Fibrosis: The Metabolic Burden as a Potent Modifier of HCC Risk

Evidence consistently shows that metabolic comorbidities, particularly type 2 diabetes mellitus (T2D), dramatically amplify HCC risk in MASLD, even before the onset of cirrhosis. Patients with MASLD and T2D often experience a two- to eightfold increase in HCC risk, especially when compounded by other metabolic traits such as hypertension, dyslipidemia, and obesity. These findings highlight the importance of integrating metabolic risk factors into surveillance strategies. Consequently, a risk-stratified approach that accounts for metabolic burden alongside fibrosis stage is critical for effective and cost-efficient HCC surveillance in noncirrhotic MASLD.

Clinical Features and Predictive Models: Refining HCC Risk Stratification

Large-scale cohort studies reveal that demographic factors like age and sex, combined with metabolic traits including T2D, chronic kidney disease, and cardiovascular disease, independently elevate HCC risk in noncirrhotic MASLD. Notably, males over 70 years with T2D represent a subgroup with significantly higher HCC incidence. Predictive tools such as the HCC-RIFLE score incorporate variables like age, sex, diabetes, BMI, and liver enzyme levels to classify patients into low, moderate, and high-risk categories. Although promising, these models require further validation across diverse populations to ensure broad clinical utility. Healthcare professionals should consider these refined risk tools to identify patients who might benefit from surveillance beyond traditional fibrosis-based criteria.

Noninvasive Fibrosis Tests and Liver Stiffness: Valuable but Limited Tools

Noninvasive fibrosis tests (NITs), including the Fibrosis-4 Index (FIB-4) and NAFLD fibrosis score, have proven useful for fibrosis staging and correlate with HCC risk. However, their predictive accuracy in noncirrhotic MASLD remains imperfect. Some patients with noncirrhotic HCC present low FIB-4 scores, suggesting that NITs alone may miss high-risk individuals. Liver stiffness measurement (LSM) via transient elastography offers additional prognostic value; elevated stiffness correlates with increased HCC risk. Yet, misclassification risks exist, as fibrosis progression during follow-up can confound results. Clinicians should thus interpret NITs and LSM cautiously and in conjunction with metabolic and clinical parameters.

Genetic and Epigenetic Insights: Unlocking Early Risk Indicators

Genetic predisposition plays a pivotal role in MASLD progression and hepatocarcinogenesis. Variants in genes such as PNPLA3, TM6SF2, and MBOAT7 correlate strongly with steatosis, fibrosis, and HCC risk, including in noncirrhotic patients. Polygenic risk scores combining these variants offer potential for early identification of high-risk individuals. Additionally, epigenetic modifications driven by metabolic factors create a pro-oncogenic environment that sustains cancer risk even after metabolic improvement, a phenomenon termed “metabolic memory.” While promising, the integration of genetic and epigenetic markers into clinical practice demands further validation and cost-effectiveness evaluation.

Multi-Omics and Machine Learning: Pioneering Precision Risk Stratification

Advancements in multi-omics and artificial intelligence (AI) have revolutionized the understanding of MASLD heterogeneity and HCC risk. Transcriptomic profiling of liver tissue and blood-based secretome signatures enable biological risk stratification beyond conventional markers. Metabolomic analyses identify circulating metabolites associated with future HCC development, offering early predictive potential.

Machine learning (ML) algorithms excel at integrating complex datasets encompassing clinical, genetic, metabolic, and imaging variables. Unsupervised clustering has revealed distinct MASLD phenotypes with varying prognoses. Furthermore, ML models, including gradient boosting and deep learning, demonstrate high accuracy in predicting HCC risk by capturing subtle interactions among risk factors. For instance, combining routine clinical data with FIB-4, hypertension status, and laboratory values enhances prediction performance.

However, ML applications face challenges such as data heterogeneity, class imbalance, and limited generalizability. Despite these obstacles, AI-driven approaches promise personalized surveillance strategies that target high-risk noncirrhotic MASLD patients efficiently.

Clinical Implications: Toward Targeted, Cost-Effective HCC Surveillance in MASLD

Given the vast heterogeneity and metabolic complexity of MASLD, healthcare professionals must move beyond fibrosis-centric paradigms. Incorporating metabolic comorbidities, genetic predisposition, and advanced biomarker panels is vital to identify noncirrhotic patients at elevated HCC risk. This precision approach permits targeted surveillance, optimizing resource allocation and improving early HCC detection.

Although current noninvasive tools offer valuable risk insights, their limitations necessitate supplementary strategies, including AI and multi-omics integration. Prospective validation and comparative effectiveness studies will be crucial before widespread clinical adoption.

Conclusion

The evolving landscape of MASLD-associated hepatocellular carcinoma demands innovative risk assessment frameworks. Recognizing the significant burden of noncirrhotic HCC, healthcare professionals should embrace multifactorial models that integrate metabolic, genetic, and biomarker data. Machine learning and multi-omics technologies offer unprecedented opportunities to refine risk stratification, enabling personalized and cost-efficient surveillance. Ultimately, these advancements hold promise for mitigating MASLD-related HCC morbidity and mortality through earlier detection and intervention.

Source: https://pubmed.ncbi.nlm.nih.gov/41977422/

LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT